Publications (129) Angel Concha Lopez publications

2024

  1. Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1143-1173

  2. The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1093-1122

2023

  1. Expression of Epithelial and Mesenchymal Markers in Plasmatic Extracellular Vesicles as a Diagnostic Tool for Neoplastic Processes

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2022

  1. Cytology Smears: An Enhanced Alternative Method for Colorectal Cancer pN Stage—A Multicentre Study

    Cancers, Vol. 14, Núm. 24

  2. Molecular Detection of Lymph Node Metastases in Lung Cancer Patients Using the One-Step Nucleic Acid Amplification Method:Clinical Significance and Prognostic Value

    Cells, Vol. 11, Núm. 24

  3. Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?

    Cancers, Vol. 14, Núm. 14

  4. Role of the E3 ubiquitin-ligase Hakai in intestinal inflammation and cancer bowel disease

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Autophagy Activation by Resveratrol Reduces Severity of Experimental Rheumatoid Arthritis

    Molecular Nutrition and Food Research, Vol. 65, Núm. 2

  2. CRC: A Darwinian model of cellular immunoselection

    Foundations of Colorectal Cancer (Elsevier), pp. 529-541

  3. Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer? (Virchows Archiv, (2021), 479, 4, (853-857), 10.1007/s00428-021-03104-7)

    Virchows Archiv

  4. Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future

    Foundations of Colorectal Cancer (Elsevier), pp. 207-230

  5. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

    Virchows Archiv, Vol. 479, Núm. 4, pp. 853-857

  6. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2020

  1. Hakin-1, a new specific small-molecule inhibitor for the E3 ubiquitin-ligase Hakai, inhibits carcinoma growth and progression

    Cancers, Vol. 12, Núm. 5

  2. Heat shock protein 90 chaperone regulates the E3 ubiquitin-ligase hakai protein stability

    Cancers, Vol. 12, Núm. 1

2019

  1. 2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

    Revista Espanola de Patologia, Vol. 52, Núm. 1, pp. 33-44

  2. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

    Breast Cancer: Targets and Therapy, Vol. 11, pp. 29-42

2018

  1. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1361-1372

  2. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

    Immunogenetics, Vol. 70, Núm. 10, pp. 647-659

  3. HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape

    Oncotarget, Vol. 9, Núm. 3, pp. 4120-4133